Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Multiple sclerosis relapse? 6,478 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6,478 reports of Multiple sclerosis relapse have been filed in association with NATALIZUMAB (TYRUKO). This represents 10.1% of all adverse event reports for NATALIZUMAB.

6,478
Reports of Multiple sclerosis relapse with NATALIZUMAB
10.1%
of all NATALIZUMAB reports
96
Deaths
3,253
Hospitalizations

How Dangerous Is Multiple sclerosis relapse From NATALIZUMAB?

Of the 6,478 reports, 96 (1.5%) resulted in death, 3,253 (50.2%) required hospitalization, and 55 (0.8%) were considered life-threatening.

Is Multiple sclerosis relapse Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 6,478 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948) Asthenia (1,945)

What Other Drugs Cause Multiple sclerosis relapse?

DIMETHYL (6,852) FINGOLIMOD (6,728) INTERFERON BETA-1A (5,931) TERIFLUNOMIDE (4,745) GLATIRAMER (3,695) DALFAMPRIDINE (3,322) OCRELIZUMAB (2,326) OFATUMUMAB (1,525) INTERFERON BETA-1B (1,229) PEGINTERFERON BETA-1A (945)

Which NATALIZUMAB Alternatives Have Lower Multiple sclerosis relapse Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Multiple sclerosis relapse Reports All Drugs Causing Multiple sclerosis relapse NATALIZUMAB Demographics